N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation

Author:

Hijazi Ziad,Wallentin Lars,Siegbahn Agneta,Andersson Ulrika,Christersson Christina,Ezekowitz Justin,Gersh Bernard J.,Hanna Michael,Hohnloser Stefan,Horowitz John,Huber Kurt,Hylek Elaine M.,Lopes Renato D.,McMurray John J.V.,Granger Christopher B.

Funder

Bristol-Myers Squibb, Co.

Pfizer Inc.

Bristol-Myers Squibb Co.

Boehringer-Ingelheim

AstraZeneca, Merck/Schering-Plough, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline

AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, Schering-Plough

Boehringer-Ingelheim, AstraZeneca, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, and Schering-Plough/Merck

AstraZeneca and Boehringer-Ingelheim

Bristol-Myers Squibb/Pfizer

Alere, AstraZeneca, Amgen, Abbott, Servier, Johnson & Johnson, Pfizer, and Bristol-Myers Squibb

sanofi-aventis, St. Jude Medical, Boehringer-Ingelheim, Cardiome, Pfizer, Bayer, and Bristol-Myers Squibb

sanofi-aventis, Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim, Medtronic, and St. Jude Medical

Bristol-Myers Squibb and Pfizer

AstraZeneca, Bristol-Myers Squibb/Pfizer, Boehringer-Ingelheim, Bayer, Daiichi Sankyo, and sanofi-aventis

Johnson & Johnson, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Pfizer, and Ortho-McNeil-Janssen

Boehringer Ingelheim and Bayer

Bristol-Myers Squibb, AstraZeneca, Boehringer-Ingelheim, and Daiichi Sankyo

Bristol-Myers Squibb and Boehringer-Ingelheim

Bristol-Myers Squibb, Boehringer-Ingelheim, Astellas, AstraZeneca, GlaxoSmithKline, Medtronic Foundation, Merck, sanofi-aventis, and the Medicines Company

Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim, AstraZeneca, Eli Lily, GlaxoSmithKline, Hoffman-La Roche, Novartis, Otsuka, Sanofi-Aventis, and the Medicines Company

Pfizer, Novartis, Otsuka, and Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3